and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at ...

Neutropenia in individuals with a congenital defect or patients with cancer who are undergoing chemotherapy is generally treated with granulocyte colony-stimulating factor (G-CSF) to restore ...

The company is planning to extend its uses into other disorders and has a phase 3 programme on the go in patients with idiopathic, cyclic and congenital neutropenia. GlobalData has predicted sales ...